BC
NGNE icon

Boxer Capital’s Neurogene NGNE Stock Holding History

Boxer Capital’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-75,053
Closed -$10.9M – 84
2021
Q3 		$10.9M Hold
75,053
– – 0.38% 58
2021
Q2 		$13.9M Hold
75,053
– – 0.49% 59
2021
Q1 		$18.5M Hold
75,053
– – 0.63% 46
2020
Q4 		$21.2M Hold
75,053
– – 0.68% 42
2020
Q3 		$18M Buy
75,053
+24,590
+49% +$5.96M 0.62% 39
2020
Q2 		$16.8M Hold
50,463
– – 0.74% 36
2020
Q1 		$11.5M Hold
50,463
– – 0.78% 33
2019
Q4 		$12.4M Buy
+50,463
New +$5.03M 0.7% 34
2018
Q2 		– Sell
-37,375
Closed -$10.5M – 29
2018
Q1 		$10.5M Buy
37,375
+21,750
+139% +$6.01M 1.12% 21
2017
Q4 		$3.67M Hold
15,625
– – 0.67% 22
2017
Q3 		$4.43M Sell
15,625
-10,625
-40% -$3.05M 1.01% 19
2017
Q2 		$7.39M Sell
26,250
-17,638
-40% -$5.05M 1.76% 14
2017
Q1 		$14.7M Hold
43,888
– – 3.2% 9
2016
Q4 		$14.5M Hold
43,888
– – 5.61% 7
2016
Q3 		$11.7M Hold
43,888
– – 5.26% 8
2016
Q2 		$5.81M Buy
43,888
+2,887
+7% +$459K 5.15% 9
2016
Q1 		$7.23M Buy
41,001
+530
+1% +$103K 7.08% 7
2015
Q4 		$10.1M Buy
+40,471
New +$10.7M 8.72% 2

Other funds holding NGNE

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Boxer Capital's NGNE Position: Q4 2021 in Review

Boxer Capital sold out of Neurogene (NGNE) in Q4 2021, closing a stake of 75,053 shares — an estimated $10.9M sold.

Boxer Capital first reported a position in NGNE in Q4 2015 and held it in 18 quarters. The position peaked at $21.2M in Q4 2020. 80 funds tracked by Wall St. Rank hold NGNE as of Q4 2021.

  • Boxer Capital reported no remaining Neurogene position as of Q4 2021 after selling out during the quarter.
  • Boxer Capital sold 75,053 Neurogene shares in Q4 2021, an estimated $10.9M.
  • Boxer Capital first reported a position in Neurogene in Q4 2015 and held it in 18 quarters.
  • Boxer Capital's Neurogene position peaked at $21.2M in Q4 2020.
  • 80 funds tracked by Wall St. Rank held Neurogene as of Q4 2021.

Based on Boxer Capital's 13F filing for Q4 2021, filed 14 Feb 2022.